Compare Biogen Inc (BIIB) vs Marathon Digital Holdings Inc (MARA) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

MARA Holdings trades at $12.19, down 3.25% in the last session. The stock faces bearish technical signals and has missed earnings estimates for three consecutive quarters, with a net income margin of -234.83% in 2025. Recent news highlights the company's strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW of power capacity, positioning it for potential growth in high-performance computing.

The outlook is mixed: analyst consensus is a Buy with a $17.88 price target, but significant execution risks exist amid persistent losses and high cash burn. Investors must weigh the AI pivot's long-term potential against near-term financial instability and competitive pressures in the evolving digital infrastructure market.